We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Accept Cookies
- 1-631-338-8059
info@cd-genomics.com
info@cd-genomics.com
The CD Lung Cancer RNA Panel (ALK, RET, ROS1, MET) combined reverse transcription, subsequent mutant, and reference gene amplification, and detected a total of 47 mutation sites in 8 reactions. And the kit minimizes hands-on time and reduces the risk of contamination. Non-small cell lung cancer (NSCLC) is often found to be associated with abnormal tyrosine kinase activity, which is associated with chromosomal translocations of ALK, ROS1, and RET. To predict response to tyrosine kinase inhibitors (TKIs) (crizotinib, ceritinib, and alectinib) in NSCLC by detecting mutations in ALK and ROS1. Lung cancer patients with RET fusion genes may be candidates for RET inhibitors (vandetanib and cabozantinib) already approved for thyroid cancer treatment.
Works with FFPE and fresh frozen samples.
One step RT-qPCR.
Simple setup and interpretation.
Includes internal control.
ALK Fusion Gene Variant Chromosomal Translocation
EML4-ALK E13; A20
E20; A20
E20; ins18A20
E6; A20
E6ins33; A20
E6; ins18A20
E14ins11; del49A20
E2; A20
E2; ins117A20
E13; ins69A20
E14; del14A20
E14; del36A20
E17; ins30A20
E17ins61; ins34A20
E17del58ins39; A20
E17ins65; A20
E17; ins68A20
E15del60; del71A20
E18; A20
E3; ins53A20
E6; A19
| Sequencing Platform: | Real-time PCR |
| Storage: | Store in < -20℃ freezer. Repeated thawing and freezing should be avoided. |
| Method: | Real-time qualitative PCR |
| Equipment Required: | Real-time PCR instrument (VIC, FAM and CY5) |
| Required Reagents: | RNA extraction kit, pipettors and filter tips |
| ShippingCondition: | Dry ice |
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to info@cd-genomics.com for inquiries.
Please fill out the form below: ×
